BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23054210)

  • 1. Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells.
    Ali A; Sidorova TS; Matesic DF
    Invest New Drugs; 2013 Jun; 31(3):525-34. PubMed ID: 23054210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells.
    Matesic DF; Villio KN; Folse SL; Garcia EL; Cutler SJ; Cutler HG
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):741-54. PubMed ID: 16254733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells.
    Curless BP; Uko NE; Matesic DF
    Invest New Drugs; 2019 Oct; 37(5):902-911. PubMed ID: 30542835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of the natural product, chaetoglobosin K, on lindane- and dieldrin-induced changes in astroglia: identification of activated signaling pathways.
    Sidorova TS; Matesic DF
    Pharm Res; 2008 Jun; 25(6):1297-308. PubMed ID: 18040759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p38 MAPK activation, JNK inhibition, neoplastic growth inhibition, and increased gap junction communication in human lung carcinoma and Ras-transformed cells by 4-phenyl-3-butenoic acid.
    Matesic DF; Sidorova TS; Burns TJ; Bell AM; Tran PL; Ruch RJ; May SW
    J Cell Biochem; 2012 Jan; 113(1):269-81. PubMed ID: 21898549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
    Song P; Song B; Liu J; Wang X; Nan X; Wang J
    Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies.
    Matesic DF; Ali A; Sidorova TS; Burns TJ
    Curr Bioact Compd; 2013; 9(3):255-262. PubMed ID: 25404879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin and epidermal growth factor stimulate adipophilin synthesis in HC11 mouse mammary epithelial cells via the PI3-kinase/Akt/mTOR pathway.
    Pauloin A; Chanat E
    Biochim Biophys Acta; 2012 May; 1823(5):987-96. PubMed ID: 22426621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
    Shan F; Shao Z; Jiang S; Cheng Z
    Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways.
    Liu SL; Lin X; Shi DY; Cheng J; Wu CQ; Zhang YD
    Arch Biochem Biophys; 2002 Oct; 406(2):173-82. PubMed ID: 12361705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.
    Okudela K; Hayashi H; Ito T; Yazawa T; Suzuki T; Nakane Y; Sato H; Ishi H; KeQin X; Masuda A; Takahashi T; Kitamura H
    Am J Pathol; 2004 Jan; 164(1):91-100. PubMed ID: 14695323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma.
    Zuo Q; Shi M; Chen J; Liao W
    Biomed Pharmacother; 2011 Jun; 65(3):168-74. PubMed ID: 21602020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EGF receptor activates ERK but not JNK Ras-dependently in basal conditions but ERK and JNK activation pathways are predominantly Ras-independent during cardiomyocyte stretch.
    Duquesnes N; Vincent F; Morel E; Lezoualc'h F; Crozatier B
    Int J Biochem Cell Biol; 2009 May; 41(5):1173-81. PubMed ID: 19015044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Akt/GSK3β and Akt/Bcl-2 signaling pathways in nickel-transformed BEAS-2B cells.
    Pan JJ; Chang QS; Wang X; Son YO; Liu J; Zhang Z; Bi YY; Shi X
    Int J Oncol; 2011 Nov; 39(5):1285-94. PubMed ID: 21837363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445.
    Tikoo A; Cutler H; Lo SH; Chen LB; Maruta H
    Cancer J Sci Am; 1999; 5(5):293-300. PubMed ID: 10526670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
    Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
    Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.